Neuroscience Today—May 20, 2026

This week’s Neuroscience update highlights CNS delivery advances, clinical and commercial progress, AI-enabled stratification, and real-world care gaps.

In Today’s Newsletter

Dive deeper

💊 Oncotelic highlights intranasal CNS delivery [1] [US • 14 May 2026]

https://www.oncotelic.com/press-releases/
Context: Oncotelic Therapeutics highlighted its proprietary intranasal nose-to-brain platform for direct CNS delivery.
Key point: BioMedWire editorial discussed CNS drug delivery barriers, Alzheimer’s disease, biodefense, and blood-brain barrier access.
Implication: Signals pipeline investment and modality expansion.

🧬 Dyno launches AI-engineered AAV capsids [2] [US • 14 May 2026]

https://www.biospace.com/press-releases/dyno-therapeutics-launches-two-new-aav-capsids-and-ai-platform-for-rare-disease-therapeutic-development-at-the-2026-american-society-of-gene-cell-therapy-asgct-annual-meeting
Context: Dyno launched Dyno-9zh for CNS delivery and Dyno-n96 for muscle delivery, with updates on Dyno-yp2, Dyno-bn8, Dyno Psi-1, and Dyno Phi.
Key point: Dyno Therapeutics presented updates at ASGCT 2026, including NHP and mouse data for CNS and muscle delivery capsids.
Implication: Signals pipeline investment and modality expansion.

☢️ Plus advances REYOBIQ and CNSide rollout [3] [US • 16 May 2026]

https://www.manilatimes.net/2026/05/16/tmt-newswire/globenewswire/plus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-on-reyobiq-clinical-program-and-cnside-commercial-rollout/2345286
Context: Plus said CNSide coverage reached about 81 million covered lives and REYOBIQ received FDA Orphan Drug Designation for pediatric malignant gliomas.
Key point: Plus Therapeutics reported Q1 2026 results, REYOBIQ clinical updates, and CNSide commercial progress.
Implication: May expand screening, initiation, and follow-up at scale.

🧠 Cantex and Headlamp partner on azeliragon AI stratification [4] [US • 13 May 2026]

https://www.prnewswire.com/news-releases/cantex-and-headlamp-health-forge-strategic-partnership-to-accelerate-azeliragon-development-via-agentic-precision-neuropsychiatry-for-severe-depression-and-fatigue-in-patients-with-multiple-sclerosis-302770433.html
Context: Cantex Pharmaceuticals and Headlamp Health will use Lumos AI to identify responder and non-responder phenotypes across azeliragon data.
Key point: Azeliragon is described as an oral, BBB-penetrant clinical-stage RAGE inhibitor for severe depression and fatigue in MS.
Implication: Signals pipeline investment and modality expansion.

📊 Neurocrine presents INGREZZA real-world TD data [5] [US • 18 May 2026]

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-presents-real-world-data-highlighting
Context: Neurocrine said 96% of mild TD patients had clinician-reported movement improvement after INGREZZA, and 86% improved within four weeks.
Key point: The clinician survey included 128 clinicians and 315 adults with TD on INGREZZA, with a mild TD subgroup of 90 patients.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🔎 Teva reports TD diagnosis gap in younger adults [6] [US/Israel • 18 May 2026]

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Study-Finds-Only-23-of-Younger-Adults-with-Mood-Disorders-and-Tardive-Dyskinesia-TD-Symptoms-Are-Formally-Diagnosed-with-TD-Despite-Widespread-Impact/default.aspx
Context: Teva reported that 23% of adults aged 18–29 with mood disorders and TD symptoms had a formal TD diagnosis, despite 85% having moderate to severe impact.
Key point: IMPACT-TD Registry analysis evaluated 211 adults with TD and mood disorders who were not receiving VMAT2 inhibitor therapy at enrollment.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧬 JCR presents preclinical JUST-AAV CNS delivery data [7] [Japan • 18 May 2026]

https://www.businesswire.com/news/home/20260518596351/en/JCR-Pharmaceuticals-Presents-Preclinical-Gene-Therapy-Data-that-Demonstrate-Promising-Central-Nervous-System-Uptake-at-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT-29th-Annual-Meeting
Context: JCR said JUST-AAV and related TfR-targeted approaches improved CNS delivery and reduced liver accumulation versus conventional AAV9 in preclinical models.
Key point: JCR Pharmaceuticals presented preclinical JUST-AAV data at ASGCT 2026, including GM1 gangliosidosis, CLN1, CLN2, and Alexion collaboration data.
Implication: Signals pipeline investment and modality expansion.

Why it Matters

CNS delivery remains a central bottleneck across small molecules, radiopharmaceuticals, biologics, and gene therapies.
ASGCT 2026 updates from Dyno and JCR point to continued investment in BBB-crossing and liver-detargeted AAV platforms.
Plus Therapeutics is pairing a CNS radiopharmaceutical program with a CSF diagnostic commercialization strategy.
Neuropsychiatry data from Neurocrine and Teva highlight TD burden, real-world treatment outcomes, and diagnosis gaps.
AI-enabled patient stratification is moving into clinical development workflows for MS-related depression and fatigue.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What did Dyno Therapeutics add to its AAV portfolio?

Dyno launched Dyno-9zh for CNS delivery and Dyno-n96 for muscle delivery, while updating Dyno-yp2 and Dyno-bn8 data. The company also described Dyno Psi-1 and Dyno Phi AI platform updates. [2]

What is Plus Therapeutics’ REYOBIQ update?

Plus reported FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and said FDA feedback supported its LM development plan. The company is preparing toward pivotal-trial readiness. [3]

How is Headlamp Health involved in azeliragon development?

Headlamp will apply its Lumos AI platform to azeliragon development data from Cantex. The goal is to identify responder and non-responder phenotypes in MS-related severe depression and fatigue. [4]

What did Neurocrine report about INGREZZA in mild TD?

Neurocrine reported clinician-survey data in 90 mild TD patients, with 96% showing clinician-reported improvement in uncontrolled movements after INGREZZA. The analysis is real-world and based on chart data and clinician recall. [5]

What diagnostic gap did Teva identify in IMPACT-TD?

Teva reported that only 23% of adults aged 18–29 with mood disorders and TD symptoms had a formal TD diagnosis, despite 85% having moderate to severe TD impact. [6]

What is JCR’s JUST-AAV platform designed to do?

JUST-AAV is a preclinical AAV platform designed to improve CNS and/or muscle delivery and reduce liver tropism. JCR presented data in GM1 gangliosidosis and CLN mouse models, plus Alexion collaboration data. [7]

Entities / Keywords

Oncotelic Therapeutics, OTLC, intranasal nose-to-brain delivery, N2B, BBB, CNS drug delivery
Dyno Therapeutics, Dyno-9zh, Dyno-n96, Dyno-yp2, Dyno-bn8, Dyno Psi-1, Dyno Phi, AAV capsids, ASGCT 2026
Plus Therapeutics, REYOBIQ, rhenium Re186 obisbemeda, CNSide, ReSPECT-LM, ReSPECT-GBM, pediatric malignant gliomas
Cantex Pharmaceuticals, Headlamp Health, Lumos AI, azeliragon, RAGE inhibitor, multiple sclerosis, depression, fatigue
Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia, TD, VMAT2 inhibitor, APA 2026
Teva Pharmaceutical Industries, IMPACT-TD Registry, mood disorders, bipolar disorder, depression, TD diagnosis gap
JCR Pharmaceuticals, JUST-AAV, GM1 gangliosidosis, CLN1, CLN2, TfR, AAV9, Alexion, AstraZeneca Rare Disease